Pernix Therapeutics Holdings Inc (NASDAQ:PTX)’s Trend Up, Especially After Decreased Shorts

August 10, 2018 - By James Guidry

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) Logo

The stock of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) registered a decrease of 2.7% in short interest. PTX’s total short interest was 2.28M shares in August as published by FINRA. Its down 2.7% from 2.35 million shares, reported previously. With 72,400 shares average volume, it will take short sellers 32 days to cover their PTX’s short positions. The short interest to Pernix Therapeutics Holdings Inc’s float is 21.59%.

The stock decreased 13.16% or $0.25 during the last trading session, reaching $1.65. About 142,666 shares traded or 117.02% up from the average. Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) has declined 43.49% since August 10, 2017 and is downtrending. It has underperformed by 56.06% the S&P500.

Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. The company has market cap of $19.59 million. It targets underserved therapeutic areas, such as central nervous system , including neurology, pain, and psychiatry. It currently has negative earnings. The companyÂ’s products comprise Treximet, a fixed dose combination product indicated for the treatment of acute migraine; Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; and Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance.

More recent Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) news were published by: Streetinsider.com which released: “Form 8-K PERNIX THERAPEUTICS HOLD For: Aug 01” on August 01, 2018. Also Globenewswire.com published the news titled: “Pernix Therapeutics Reports Second Quarter 2018 Financial Results” on August 09, 2018. Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo’s Positive Trial Results, Insys Earnings” with publication date: August 09, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: